Divi's Laboratories News and Updates

Name: Latest research reports of Divi's Laboratories Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Divi's Laboratories from all sources in a single place.

Divi's Laboratories Ltd.

06 Apr 2026

6309.50

0.38%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The outlook remains positive, supported by Divi's strong positioning in custom synthesis and a diversified pipeline, with management highlighting active engagement with global innovator customers and multiple projects progressing through development and validation. Ongoing capacity additions along with a focus on disciplined execution and supply reliability are expected to support future growth, while the nutraceuticals business continues to provide healthy momentum and diversification. The company has also completed construction of a dedicated peptide facility, strengthening its capabilities in this fast-evolving segment, and...

Geojit BNP Paribas upgraded Divi's Laboratories Ltd. to Hold with a price target of 6336.0 on 06 Apr, 2026.

Divi's Laboratories Ltd.

11 Feb 2026

6309.50

0.38%

Divi's Laboratories Results Earnings Call for Q3FY26

Conference Call with Divi's Laboratories Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Divi's Laboratories Ltd.

11 Dec 2025

6309.50

0.38%

Sharekhan upgrades Divi's Labs to 'Buy' on strong FY26-28 growth visibility

Business Standard

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Divi's Laboratories Ltd. is trading above its 150 day SMA of 6278.8

Divi's Laboratories Ltd.

20 Nov 2025

6309.50

0.38%

Healthy CS traction and favorable mix boosted profitability even as generics remained soft

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.

Geojit BNP Paribas upgraded Divi's Laboratories Ltd. to Hold with a price target of 6336.0 on 06 Apr, 2026.

Divi's Laboratories Ltd.

10 Nov 2025

6309.50

0.38%

Divi's Labs (HOLD): Key molecule LOE to risk upside growth in Custom Synthesis

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 3%/9%/11% above estimates. EBITDA margin reported 170 bps above estimates.

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

10 Nov 2025

6309.50

0.38%

Divi's Laboratories (DIVI IN) Q2FY26 Result Update Peptides...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Geojit BNP Paribas upgraded Divi's Laboratories Ltd. to Hold with a price target of 6336.0 on 06 Apr, 2026.

Divi's Laboratories Ltd.

09 Nov 2025

6309.50

0.38%

Generics continue to drag growth, CS outlook unchanged

Sell: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.

Divi's Laboratories .. has an average target of 6600.67 from 6 brokers.

Divi's Laboratories Ltd.

08 Nov 2025

6309.50

0.38%

Operating leverage and CS strength support margins

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered better-than-expected performance in 2Q with a 4%/10%/10% beat on revenue/EBITDA/PAT.

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

07 Nov 2025

6309.50

0.38%

Divi's Laboratories Results Earnings Call for Q2FY26

Conference Call with Divi's Laboratories Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Divi's Laboratories Ltd.

13 Oct 2025

6309.50

0.38%

Divis Labs rallies 13% in 1 week; What's driving pharma stock?

Business Standard

Divis stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from emerging trends across both API and CDMO domains through innovation and capex.

Divi's Laboratories Ltd. is trading below its 200 day SMA of 6313.8

Is Divi's Laboratories Ltd. worth buying?

756 Votes:

Buy 78.17%

Sell 14.95%

Hold 6.88%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf